1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 2010, 28(13): 2181-2190.
|
3. |
Le Pechoux C, Pourel N, Barlesi F, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): An open-label, randomised, phase 3 trial. Lancet Oncol, 2022, 23(1): 104-114.
|
4. |
Zhu L, Xia B, Ma S. Postoperative radiotherapy for patients with completely resected stageⅢA-N2 non-small cell lung cancer: opt-in or opt-out. Thorac Cancer, 2022, 13(5): 659-663.
|
5. |
Lin SM, Ku HY, Hsu CY, et al. Long-term survival effect of the interval between postoperative chemotherapy and radiotherapy in patients with completely resected pathological N2 non-small-cell lung cancer. Cancers (Basel), 2021, 13(10): 2494.
|
6. |
Sinn K, Mosleh B, Steindl A, et al. Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage Ⅲ/N2 non-small-cell lung cancer: A retrospective single-center cohort study. ESMO Open, 2022, 7(2): 100466.
|
7. |
Hui Z, Men Y, Hu C, et al. Effect of postoperative radiotherapy for patients with pⅢa-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: The phase 3 PORT-C randomized clinical trial. JAMA Oncol, 2021, 7(8): 1178-1185.
|
8. |
Faivre-Finn C, Edwards JG, Hatton M. Postoperative radiation therapy should not be used for the therapy of stageⅢ-N2 NSCLC. J Thorac Oncol, 2022, 17(2): 197-199.
|
9. |
Liu J, Ladbury C, Kim J, et al. Postoperative radiation therapy should be used for completely resected stageⅢ-N2 NSCLC in select patients. J Thorac Oncol, 2022, 17(2): 194-196.
|
10. |
Pang Z, Yang Y, Ding N, et al. Optimal managements of stageⅢA (N2) non-small cell lung cancer patients: A population-based survival analysis. J Thorac Dis, 2017, 9(10): 4046-4056.
|
11. |
Wang Y, Cao Y, Wu M, et al. Effect of preoperative radiotherapy on overall survival in N2 non-small-cell lung cancer: A propensity score-matched analysis of Surveillance, Epidemiology, and End Results database. Interact Cardiovasc Thorac Surg, 2022, 35(1): ivab321.
|
12. |
Zhang H, Zhang DX, Ju T, et al. The effect of postoperative radiotherapy on the survival of patients with resectable stageⅢ-N2 non-small-cell lung cancer: A systematic review and meta-analysis. Neoplasma, 2019, 66(5): 717-726.
|
13. |
Sakib N, Li N, Zhu X, et al. Effect of postoperative radiotherapy on outcome in resectable stageⅢA-N2 non-small-cell lung cancer: An updated meta-analysis. Nucl Med Commun, 2018, 39(1): 51-59.
|
14. |
Wang SF, Mao NQ, Zhao WH, et al. Postoperative radiotherapy in pⅢA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: A meta-analysis. Medicine (Baltimore), 2022, 101(28): e29550.
|
15. |
Lei T, Li J, Zhong H, et al. Postoperative radiotherapy for patients with resectable stage III-N2 non-small cell lung cancer: A systematic review and meta-analysis. Front Oncol, 2021, 11: 680615.
|
16. |
Yamasaki N, Kim YH, Iwatsubo S, et al. Role of postoperative radiotherapy in patients with completely resected pⅢA-N2 non-small cell lung cancer. Clin Lung Cancer, 2022, 23(3): e171-e172.
|
17. |
Sun X, Men Y, Wang J, et al. Risk of cardiac-related mortality in stageⅢA-N2 non-small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. Thorac Cancer, 2021, 12(9): 1358-1365.
|
18. |
Wang X, Song J, Long J, et al. Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stageⅢA-N2 resected NSCLC: Analysis of the SEER database. Radiat Oncol, 2021, 16(1): 184.
|
19. |
Duan H, Liang L, Xie S, et al. The impact of order with radiation therapy in stageⅢA pathologic N2 NSCLC patients: A population-based study. BMC Cancer, 2020, 20(1): 809.
|
20. |
Gao F, Li N, Xu Y, et al. Evaluation of postoperative radiotherapy effect on survival of resected stageⅢ-N2 non-small cell lung cancer patients. Front Oncol, 2020, 10: 1135.
|
21. |
Wang S, Ma Z, Yang X, et al. Choice of postoperative radiation for stageⅢA pathologic N2 non-small cell lung cancer: Impact of metastatic lymph node number. Radiat Oncol, 2017, 12(1): 207.
|
22. |
Zarinshenas R, Ladbury C, McGee H, et al. Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stageⅢ-N2 non-small cell lung cancer. Radiother Oncol, 2022, 173: 10-18.
|
23. |
Allaeys T, Berzenji L, Lauwers P, et al. Multimodality treatment including surgery related to the type of N2 involvement in locally advanced non-small cell lung cancer. Cancers (Basel), 2022, 14(7): 1656.
|
24. |
Zhang CC, Hou RP, Xia WY, et al. Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: A real-world validation study. Lung Cancer, 2021, 156: 100-108.
|
25. |
Zeng WQ, Feng W, Xie L, et al. Postoperative radiotherapy for resected stageⅢA-N2 non-small-cell lung cancer: A population-based time-trend study. Lung, 2019, 197(6): 741-751.
|
26. |
Zhang CC, Yu W, Zhang Q, et al. A decision support framework for postoperative radiotherapy in patients with pathological N2 non-small cell lung cancer. Radiother Oncol, 2022, 173: 313-318.
|
27. |
Xu L, Xie HN, Chen XK, et al. Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resectedⅢA/N2 non-small cell lung cancer: A population-based study. Thorac Cancer, 2021, 12(6): 760-767.
|